Cross-protection against drifted influenza viruses: Options offered by adjuvanted and intradermal vaccines

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 3, 2013, Pages 582-590

  Orsi, Andrea ^a   Ansaldi, Filippo ^a,b   De Florentiis, Daniela ^a   Ceravolo, Antonella ^a   Parodi, Valentina ^a   Canepa, Paola ^a   Coppelli, Martina ^a   Icardi, Giancarlo ^a,b   Durando, Paolo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Adjuvants; Antigenic drift; Cross protection; Influenza vaccine; Intradermal; MF59

Indexed keywords

DNA VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; MIFAMURTIDE; RECOMBINANT VACCINE; VIROSOME VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; SUBUNIT VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIGENICITY; CONFERENCE PAPER; CROSS PROTECTION; CROSS REACTION; DNA IMMUNIZATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HOST RESISTANCE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; NONHUMAN; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VIRUS IMMUNITY; VIRUS STRAIN; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; INFLUENZA, HUMAN; INTRADERMAL DRUG ADMINISTRATION; ORTHOMYXOVIRUS;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; CROSS PROTECTION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; ORTHOMYXOVIRIDAE; POLYSORBATES; SQUALENE; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 84874743909     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23239     Document Type: Conference Paper

References (90)

1. Stöhr K. Influenza-WHO cares. Lancet Infect Dis 2002; 2:517; PMID:12206966; http://dx.doi.org/10.1016/S1473-3099(02)00366-3.
2. Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med 2000; 51:407-21; PMID:10774473; http://dx.doi.org/10.1146/annurev. med.51.1.407. (Pubitemid 30216046)
3. Both GW, Sleigh MJ, Cox NJ, Kendal AP. Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J Virol 1983; 48:52-60; PMID:6193288. (Pubitemid 13006721)
4. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982; 31:417-27; PMID:6186384; http://dx.doi.org/10.1016/0092-8674(82)90135-0. (Pubitemid 13178866)
5. Cox NJ, Black RA, Kendal AP. Pathways of evolution of influenza A (H1N1) viruses from 1977 to 1986 as determined by oligonucleotide mapping and sequencing studies. J Gen Virol 1989; 70:299-313; PMID:2732691; http://dx.doi.org/10.1099/0022-1317-70-2-299. (Pubitemid 19051661)
6. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289:373-8; PMID:6162101; http://dx.doi.org/10.1038/289373a0. (Pubitemid 11135143)
7. Wang ML, Skehel JJ, Wiley DC. Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera. J Virol 1986; 57:124-8; PMID:3941436. (Pubitemid 16147925)
8. Treanor J. Influenza vaccine-outmaneuvering antigenic shift and drift. N Engl J Med 2004; 350:218-20; PMID:14724300; http://dx.doi.org/10.1056/ NEJMp038238. (Pubitemid 38067634)
9. Koelle K, Cobey S, Grenfell B, Pascual M. Epochal evolution shapes the phylodynamics of interpandemic influenza A (H3N2) in humans. Science 2006; 314:1898-903; PMID:17185596; http://dx.doi.org/10.1126/science.1132745. (Pubitemid 46026107)
10. Aymard M, Valette M, Lina B, Thouvenot D. Surveillance and impact of influenza in Europe. Groupe Régional d'Observation de la Grippe and European Influenza Surveillance Scheme. Vaccine 1999; 17(Suppl 1):S30-41; PMID:10471178; http://dx.doi.org/10.1016/S0264-410X(99)00103-6. (Pubitemid 29366931)
11. Klimov A, Simonsen L, Fukuda K, Cox N. Surveillance and impact of influenza in the United States. Vaccine 1999; 17(Suppl 1):S42-6; PMID:10471179; http://dx.doi.org/10.1016/S0264-410X(99)00104-8. (Pubitemid 29366932)
12. Ansaldi F, Icardi G, Gasparini R, Campello C, Puzelli S, Bella A, et al. New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004-2005 season. J Clin Microbiol 2005; 43:3027-9; PMID:15956452; http://dx.doi.org/10.1128/JCM.43.6.3027-3029.2005.
13. Paget WJ, Meerhoff TJ, Meijer A; EISS. Epidemiological and virological assessment of influenza activity in Europe during the 2003-2004 season. Euro Surveill 2005; 10:107-11; PMID:15879646.
14. Skowronski DM, Janjua NZ, De Serres G, Winter AL, Dickinson JA, Gardy JL, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 2012; 55:332-42; PMID:22539661; http://dx.doi.org/10.1093/cid/cis431.
15. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccineinduced antibody response to this strain in the elderly. J Med Virol 2000; 61:94-9; PMID:10745239; http://dx.doi.org/10.1002/(SICI) 1 0 9 6-9071(200005)61:1<94::AID-JMV15>3. 0.CO;2-C. (Pubitemid 30191232)
16. Ansaldi F, Bacilieri S, Banfi F, Durando P, Sticchi L, Icardi G, et al. Neutralizing and hemagglutinationinhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses. Clin Vaccine Immunol 2006; 13:162-4; PMID:16426017; http://dx.doi.org/10.1128/CVI.13.1.162-164.2006.
17. Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, et al. An MF59-Adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24:3063-5; PMID:16464520; http://dx.doi.org/10. 1016/j.vaccine.2006.01.015.
18. Kojimahara N, Maeda A, Kase T, Yamaguchi N. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. Vaccine 2006; 24:5966-9; PMID:16777274; http://dx.doi.org/10. 1016/j.vaccine. 2006.05.009. (Pubitemid 44080364)
19. Bridges CB, Thompson WW, Meltzer MI, Reeve GR, Talamonti WJ, Cox NJ, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA 2000; 284:1655-63; PMID:11015795; http://dx.doi.org/10.1001/jama.284.13.1655.
20. Legrand J, Vergu E, Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 2006; 24:6605-11; PMID:16806607; http://dx.doi.org/10.1016/j.vaccine.2006.05.063. (Pubitemid 46127433)
21. Centers for Disease Control and Prevention (CDC). Preliminary assessment of the effectiveness of the 2003-04 inactivated influenza vaccine-Colorado, December 2003. WR Morb Mortal Wkly Rep 2004; 53:8-11.
22. Doherty PC, Kelso A. Toward a broadly protective influenza vaccine. J Clin Invest 2008; 118:3273-5; PMID:18802488.
23. Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007; 25:659-63; PMID:17011678; http://dx.doi.org/10.1016/ j.vaccine.2006.08.026.
24. Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-Adjuvanted influenza vaccine in elderly subjects. Vaccine 2003; 21:1268-74; PMID:12559808; http://dx.doi.org/10.1016/S0264-410X(02)00401-2. (Pubitemid 36139959)
25. Baldo V, Baldovin T, Floreani A, Carraro AM, Trivello R; Family Medicine Group of Pianiga. MF59-Adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 2007; 25:3955-61; PMID:17383057; http://dx.doi.org/10.1016/j.vaccine.2007.02.045. (Pubitemid 46616991)
26. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of nonadjuvanted and MF59-Adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43; PMID:11425416; http://dx.doi.org/10.1016/S0140-6736(00)05066-2.
27. Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-Adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210-5; PMID:15776364; http://dx.doi.org/10.1086/428948.
28. Ansaldi F, Canepa P, Ceravolo A, Valle L, de Florentiis D, Oomen R, et al. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine 2012; 30:2908-13; PMID:22342501; http://dx.doi.org/10.1016/j.vaccine.2012.02.003.
29. Straight TM, Ottolini MG, Prince GA, Eichelberger MC. Evidence of a cross-protective immune response to influenza A in the cotton rat model. Vaccine 2006; 24:6264-71; PMID:16860444; http://dx.doi.org/10.1016/j.vaccine.2006.05. 092.
30. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, Osterhaus AD, et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007; 25:612-20; PMID:17005299; http://dx.doi.org/10.1016/j.vaccine. 2006.08.036. (Pubitemid 44856111)
31. Takada A, Matsushita S, Ninomiya A, Kawaoka Y, Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 2003; 21:3212-8; PMID:12804850; http://dx.doi.org/10.1016/S0264-410X(03)00234-2. (Pubitemid 36700428)
32. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513-22; PMID:17167134; http://dx.doi.org/10. 1056/NEJMoa061850. (Pubitemid 44917499)
33. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. [Erratum in: N Engl J Med 2007; 356] [12]. N Engl J Med 2007; 356:685-96; PMID:17301299; http://dx.doi.org/10.1056/NEJMoa065368.
34. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006; 24:4475-81; PMID:16150518; http://dx.doi.org/10.1016/j.vaccine. 2005.08.012. (Pubitemid 43776768)
35. Webster RG. Potential advantages of DNA immunization for influenza epidemic and pandemic planning. Clin Infect Dis 1999; 28:225-9; PMID:10064231; http://dx.doi.org/10.1086/515123. (Pubitemid 29241204)
36. Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997; 15:865-8; PMID:9234535; http://dx.doi.org/10.1016/S0264-410X(96)00268-X. (Pubitemid 27287977)
37. Macklin MD, McCabe D, McGregor MW, Neumann V, Meyer T, Callan R, et al. Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus. J Virol 1998; 72:1491-6; PMID:9445052. (Pubitemid 28116937)
38. Justewicz DM, Morin MJ, Robinson HL, Webster RG. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. J Virol 1995; 69:7712-7; PMID:7494280.
39. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, et al. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat Med 1995; 1:583-7; PMID:7585127; http://dx.doi.org/10.1038/nm0695-583.
40. Cristillo AD, Ferrari MG, Hudacik L, Lewis B, Galmin L, Bowen B, et al. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J Gen Virol 2011; 92:128-40; PMID:21169215; http://dx.doi.org/10.1099/vir.0.023242-0.
41. Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol 2008; 180:7019-27; PMID:18453624.
42. Luke JM, Simon GG, Söderholm J, Errett JS, August JT, Gale M Jr., et al. Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine. J Virol 2011; 85:1370-83; PMID:21106745; http://dx.doi.org/ 10.1128/JVI.01250-10.
43. Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 2011; 146:448-61; PMID:21782231; http://dx.doi.org/10.1016/j. cell.2011.06.041.
44. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol 2012; 162:171-82; PMID:22981627; http://dx.doi.org/10.1016/j.jbiotec. 2012.08.012.
45. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 2007; 3:157-64; PMID:17637571; http://dx.doi.org/10.4161/hv.3.5.4175.
46. Liu X, Guo J, Han S, Yao L, Chen A, Yang Q, et al. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Vaccine 2012; 30:6527-33; PMID:22959982; http://dx.doi.org/10.1016/j.vaccine. 2012.08.054.
47. Hikono H, Miyazaki A, Mase M, Inoue M, Hasegawa M, Saito T. Induction of a cross-reactive antibody response to influenza virus M2 antigen in pigs by using a Sendai virus vector. Vet Immunol Immunopathol 2012; 146:92-6; PMID:22336036; http://dx.doi.org/10.1016/j.vetimm.2012.01.017.
48. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010; 329:1060-4; PMID:20647428; http://dx.doi.org/10.1126/science. 1192517.
49. Bianchi E, Liang X, Ingallinella P, Finotto M, Chastain MA, Fan J, et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol 2005; 79:7380-8; PMID:15919893; http://dx.doi.org/10.1128/JVI.79.12.7380-7388.2005. (Pubitemid 40756774)
50. Bruzzone B, Crovari P, Durando P, Setti M. [Influenza vaccination: advantages of new generation carriers]. Ann Ig 2002; 14(Suppl 3):11-8; PMID:12389406.
51. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-Adjuvanted vaccine. Vaccine 2001; 19:2673-80; PMID:11257408; http://dx.doi.org/10.1016/S0264-410X(00)00499-0. (Pubitemid 32234288)
52. Podda A, Del Giudice G. MF59-Adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2:197-203; PMID:12899571; http://dx.doi.org/10.1586/14760584.2.2.197.
53. Bloch KE. Sterol structure and membrane function. CRC Crit Rev Biochem 1983; 14:47-92; PMID:6340956; http://dx.doi.org/10.3109/10409238309102790.
54. Del Giudice G, Fragapane E, Bugarini R, Hora M, Henriksson T, Palla E, et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 2006; 13:1010-3; PMID:16960112; http://dx.doi.org/10.1128/CVI.00191-06. (Pubitemid 44518969)
55. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008; 26:3209-22; PMID:18462843; http://dx.doi.org/10. 1016/j.vaccine.2008.03.093.
56. Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and-seronegative adults. Clin Vaccine Immunol 2008; 15:253-9; PMID:18003811; http://dx.doi.org/10.1128/CVI.00316-07. (Pubitemid 352025530)
57. Baldo V, Menegon T, Bonello C, Floreani A, Trivello R; Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001; 19:3472-5; PMID:11348713; http://dx.doi.org/10.1016/ S0264-410X(01)00060-3. (Pubitemid 32710298)
58. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-Adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 2009; 27:6291-5; PMID:19840662; http://dx.doi.org/10.1016/j.vaccine.2009.02.004.
59. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563-71; PMID:19561422; http://dx.doi.org/10.1097/INF.0b013e31819d6394.
60. Durando P, Icardi G, Ansaldi F. MF59-Adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10:639-51; PMID:20218923; http://dx.doi.org/10.1517/14712591003724662.
61. Novartis. Vaccine and diagnostics. Data on file; 2007. 62. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-Adjuvanted influenza vaccine and a nonadjuvanted influenza vaccine in non-elderly adults. Vaccine 2003; 21:4234-7; PMID:14505903; http://dx.doi.org/10.1016/S0264-410X(03)00456-0. (Pubitemid 37130269)
62. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010; 2:ra5; PMID:20371470; http://dx.doi.org/10.1126/ scitranslmed.3000624.
63. Hannoun C, Megas F, Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004; 103:133-8; PMID:15163501; http://dx.doi.org/10.1016/j.virusres.2004.02.025. (Pubitemid 38649072)
64. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, et al. Cross-protection by MF59-Adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26:1525-9; PMID:18294741; http://dx.doi.org/10.1016/j. vaccine.2008.01.019.
65. Ansaldi F, Canepa P, Parodi V, Bacilieri S, Orsi A, Compagnino F, et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. Vaccine 2009; 27:3345-8; PMID:19200846; http://dx.doi.org/10.1016/j.vaccine. 2009.01.081.
66. Baldo V, Baldovin T, Floreani A, Fragapane E, Trivello R; Family Medicine Group. Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases. J Clin Immunol 2007; 27:542-7; PMID:17514499; http://dx.doi.org/10.1007/s10875-007-9100-4. (Pubitemid 47319253)
67. Bridges CB, Lim W, Hu-Primmer J, Sims L, Fukuda K, Mak KH, et al. Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998. J Infect Dis 2002; 185:1005-10; PMID:11930308; http://dx.doi.org/10.1086/340044. (Pubitemid 34297756)
68. Brauer V, Laghi-Pasini F, Capecchi PL, et al. Priming for pandemic influenza: Antigen-sparing MF59-Adjuvanted A /H5N1 vaccine induces immunological memory and shows cross-reactive potential in adults including the elderly. 13th International Congress on Infectious Diseases 2008, Kuala Lumpur, Malaysia, 19-22 June 2008.
69. Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, et al. Boosting immunity to influenza H5N1 with MF59-Adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003; 21:1687-93; PMID:12639491; http://dx.doi.org/10.1016/S0264-410X(02)00632-1. (Pubitemid 36287599)
70. Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012; 176:527-33; PMID:22940713; http://dx.doi.org/10.1093/aje/kws313.
71. Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, et al.; H5N1 Flu Study Group for Hong Kong, Singapore, Taiwan and Thailand. Immunogenicity and tolerability of an AS03(A)-Adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27:7428-35; PMID:19683087; http://dx.doi.org/10.1016/j.vaccine.2009.07.102.
72. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-Adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5; PMID:20034605; http://dx.doi.org/10.1016/j.vaccine.2009.12.014.
73. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, et al. Priming with AS03 A-Adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-57; PMID:19835828; http://dx.doi.org/10.1016/j.vaccine. 2009.10.017.
74. Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3:e1665; PMID:18301743; http://dx.doi.org/10.1371/journal. pone.0001665.
75. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9; PMID:17707753; http://dx.doi.org/10.1016/S0140-6736(07) 61297-5. (Pubitemid 47247854)
76. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, et al. Single dose vaccination with AS03-Adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90; PMID:19856521; http://dx.doi.org/10.1016/j. vaccine. 2009.01.040.
77. Rümke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378-88; PMID:18407382; http://dx.doi.org/10.1016/j.vaccine.2008.02.068.
78. Herzog C, Hartmann K, Künzi V, Kürsteiner O, Mischler R, Lazar H, et al. Eleven years of Inflexal V-A virosomal adjuvanted influenza vaccine. Vaccine 2009; 27:4381-7; PMID:19450630; http://dx.doi.org/10.1016/j.vaccine. 2009.05.029.
79. Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 2002; 20(Suppl 5):B17-23; PMID:12477413; http://dx.doi.org/10.1016/S0264-410X(02)00512-1. (Pubitemid 35435392)
80. Baldo V, Baldovin T, Pellegrini M, Angiolelli G, Majori S, Floreani A, et al. Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residents. Clin Dev Immunol 2010; 2010:517198; PMID:20369059; http://dx.doi.org/10.1155/2010/517198.
81. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650-8; PMID:18652550; http://dx.doi.org/10.1086/ 590434.
82. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7:1201-14; PMID:18844594; http://dx.doi.org/10.1586/14760584.7.8.1201.
83. Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system. Hum Vaccin Immunother 2012; 8:67-75; PMID:22293531.
84. Ansaldi F, de Florentiis D, Durando P, Icardi G. Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev Vaccines 2012; 11:17-25; PMID:22149703; http://dx.doi.org/10.1586/erv.11.154.
85. Durando P, Alicino C, Alberti M, Sticchi L, Turello V, Marensi L, et al.; Italian Intradermal Influenza Vaccine Working Group. Acceptance and safety of the intradermal influenza vaccine among the elderly in Italy: an on-field national study. Adv Ther 2012; 29:312-26; PMID:22529024; http://dx.doi.org/10. 1007/s12325-012-0012-1.
86. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial. Hum Vaccin 2010; 6:346-54; PMID:20372053; http://dx.doi.org/10.4161/hv.6. 4.10961.
87. Frenck RW Jr., Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine 2011; 29:5666-74; PMID:21699951; http://dx.doi.org/10.1016/j.vaccine.2011.06.010.
88. Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, et al.; VRC 304 and VRC 305 Study Teams. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012; 19:1792-7; PMID:22956656; http://dx.doi.org/10.1128/CVI.05663-11.
89. Patel SM, Atmar RL, El Sahly HM, Guo K, Hill H, Keitel WA. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis 2012; 206:1069-77; PMID:22891287; http://dx.doi.org/10.1093/infdis/jis402.
90. Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-And non-Adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine 2010; 28:4123-9; PMID:20433807; http://dx.doi.org/10.1016/j.vaccine. 2010.04.030.